Analysts expect InMode to report Q2 2026 revenue of $88.2 million and non-GAAP EPS of $0.34, as the stock currently trades at $15.85 compared to a $21.00 average price target. The primary focus for investors remains the growth rate of consumable and service revenue to see if it can offset the persistent pressure on high-cost platform sales.
Recent quarters have been marred by high interest rates which have deterred clinic owners from financing new aesthetic workstations, leading to several guidance cuts in the previous fiscal year. Management's commentary on North American inventory levels and the traction of the newer Envision and Ignite platforms will be the deciding factor for a stock recovery.